Compare Stocks

→ The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVN Avanti Helium	C$0.36 -2.7%	C$0.42	C$0.35 ▼ C$0.79	C$30.19M	1.33	121,374 shs	306,014 shs
EOG EOG Resources	$135.71 +0.3%	$125.70	$106.32 ▼ $139.67	$78.06B	1.4	3.36 million shs	1.84 million shs
IPO Renaissance IPO ETF	$38.27 +2.2%	$39.47	$27.09 ▼ $42.40	$179.87M	1.64	61,257 shs	13,808 shs
PHAR Pharming Group	$9.61 -8.0%	$10.83	$9.27 ▼ $16.71	$644.93M	0.16	2,610 shs	1,703 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVN Avanti Helium	+4.23%	-5.13%	-7.50%	-19.57%	-33.93%
EOG EOG Resources	-0.15%	+2.76%	+7.64%	+17.18%	+17.06%
IPO Renaissance IPO ETF	-0.50%	+0.83%	-9.50%	+8.11%	+37.42%
PHAR Pharming Group	-2.93%	-0.16%	-11.36%	-22.01%	-11.81%

The Next Step of Their Control Is Here … (Ad)

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVN Avanti Helium	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EOG EOG Resources	3.9225 of 5 stars	2.2	3.0	3.3	0.2	3.2	1.7	1.9
IPO Renaissance IPO ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	2.5709 of 5 stars	3.5	5.0	0.0	0.0	2.6	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVN Avanti Helium	N/A	N/A	N/A	N/A
EOG EOG Resources	2.48	Hold	$142.19	4.78% Upside
IPO Renaissance IPO ETF	0.00	N/A	$42.51	11.07% Upside
PHAR Pharming Group	3.00	Buy	$37.00	285.02% Upside

Current Analyst Ratings

Latest AVN, IPO, EOG, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	EOG EOG Resources	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
4/22/2024	EOG EOG Resources	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$147.00 ➝ $157.00
4/22/2024	EOG EOG Resources	Susquehanna Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Positive ➝ Positive	$147.00 ➝ $155.00
4/19/2024	EOG EOG Resources	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$141.00 ➝ $153.00
4/15/2024	EOG EOG Resources	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$132.00 ➝ $133.00
4/15/2024	EOG EOG Resources	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $140.00
4/11/2024	EOG EOG Resources	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$135.00 ➝ $155.00
4/10/2024	EOG EOG Resources	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$144.00
4/9/2024	EOG EOG Resources	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$145.00
4/5/2024	EOG EOG Resources	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$165.00 ➝ $163.00
3/14/2024	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVN Avanti Helium	N/A	N/A	C$0.02 per share	21.48	C$0.37 per share	N/A
EOG EOG Resources	$24.19B	3.23	$17.72 per share	7.66	$48.17 per share	2.82
IPO Renaissance IPO ETF	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	$245.32M	2.63	$0.10 per share	100.85	$3.26 per share	2.95

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVN Avanti Helium	-C$5.94M	-C$0.08	N/A	∞	N/A	N/A	-23.34%	-12.83%	6/3/2024 (Estimated)
EOG EOG Resources	$7.59B	$13.01	10.43	10.43	N/A	31.40%	25.38%	16.06%	5/2/2024 (Confirmed)
IPO Renaissance IPO ETF	N/A	N/A	42.29	∞	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	-$10.55M	-$0.14	N/A	N/A	N/A	-4.13%	-4.53%	-2.14%	5/8/2024 (Confirmed)

Latest AVN, IPO, EOG, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2024	N/A	PHAR Pharming Group	$0.0050	N/A	-$0.0050	N/A	N/A	N/A
5/2/2024	N/A	EOG EOG Resources	$2.68	N/A	-$2.68	N/A	N/A	N/A
3/14/2024	Q4 2023	PHAR Pharming Group	$0.05	-$0.03	-$0.08	-$0.02	$71.83 million	$81.20 million
2/23/2024	Q4 23	EOG EOG Resources	$3.14	$3.07	-$0.07	$2.72	$6.18 billion	$6.36 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVN Avanti Helium	N/A	N/A	N/A	N/A	N/A
EOG EOG Resources	$3.64	2.68%	+32.69%	27.98%	7 Years
IPO Renaissance IPO ETF	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Latest AVN, IPO, EOG, and PHAR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/22/2024	EOG EOG Resources	quarterly	$0.91	3.13%	4/15/2024	4/16/2024	4/30/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVN Avanti Helium	0.57	0.13	1.36
EOG EOG Resources	0.13	2.44	2.13
IPO Renaissance IPO ETF	N/A	N/A	N/A
PHAR Pharming Group	0.62	4.06	3.33

Ownership

Institutional Ownership

Company	Institutional Ownership
AVN Avanti Helium	0.88%
EOG EOG Resources	89.91%
IPO Renaissance IPO ETF	N/A
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
AVN Avanti Helium	5.34%
EOG EOG Resources	0.30%
IPO Renaissance IPO ETF	N/A
PHAR Pharming Group	2.07%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVN Avanti Helium	N/A	83.86 million	N/A	Not Optionable
EOG EOG Resources	3,050	575.22 million	573.49 million	Optionable
IPO Renaissance IPO ETF	N/A	4.70 million	N/A	Not Optionable
PHAR Pharming Group	332	67.11 million	65.72 million	Not Optionable

AVN, IPO, EOG, and PHAR Headlines

Source	Headline
	Pharming Group (NASDAQ:PHAR) Trading Down 8.8% marketbeat.com - April 26 at 5:57 PM
	Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards finance.yahoo.com - April 24 at 2:17 AM
	Pharming Group to report first quarter 2024 financial results on May 8 finance.yahoo.com - April 24 at 2:17 AM
	Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00 marketbeat.com - April 22 at 1:31 PM
	Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains? zacks.com - April 22 at 6:31 AM
	Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase americanbankingnews.com - April 21 at 4:44 AM
	Pharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35 americanbankingnews.com - April 20 at 4:40 AM
	Pharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 finanznachrichten.de - April 19 at 4:05 PM
	Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume marketbeat.com - April 19 at 1:37 PM
	Pharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029 finanznachrichten.de - April 18 at 6:18 PM
	Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 finance.yahoo.com - April 18 at 8:17 AM
	Pharming Group (NASDAQ:PHAR) Stock Price Down 6.8% marketbeat.com - April 15 at 1:55 PM
	Pharming Group (NASDAQ:PHAR) Shares Down 5% marketbeat.com - April 9 at 3:19 PM
	Enrollment completed for trial of drug to treat children with rare primary immunodeficiency outsourcing-pharma.com - April 8 at 8:50 AM
	Pharming announces completion of enrollment in pediatric clinical trial of leniolisib finance.yahoo.com - April 8 at 1:34 AM
	Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96 marketbeat.com - April 4 at 6:21 PM
	Pharming Group announces the filing of its 2023 Annual Report and Form 20-F finance.yahoo.com - April 4 at 1:14 AM
	Uber to pay $178 million in Australia taxi class action settlement msn.com - March 18 at 3:45 AM
	Pharming reports Q4 results msn.com - March 15 at 7:46 PM
	Pharming Group N.V. 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - March 14 at 9:06 AM
	Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14 finanznachrichten.de - February 29 at 6:26 AM
	Pharming Group N.V. (PHGN.F) finance.yahoo.com - February 20 at 3:10 PM
	Pharming Group N.V.: Pharming Group to participate in February investor conferences finanznachrichten.de - February 8 at 3:55 AM
	Pharming Group to participate in February investor conferences finance.yahoo.com - February 8 at 3:55 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avanti Helium

CVE:AVN

Avanti Helium Corp. acquires, explores, and develops helium projects in Canada and the United States. The company's principal project is its 100% owned Greater Knappen Project, which covers an area of approximately 70,140 acres located in the Southern Alberta and Northwestern Montana. The company was formerly known as Avanti Energy Inc. and changed its name to Avanti Helium Corp. in August 2022. Avanti Helium Corp. was incorporated in 2011 and is headquartered in Calgary, Canada.

EOG Resources

NYSE:EOG

EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, natural gas liquids, and natural gas primarily in producing basins in the United States, the Republic of Trinidad and Tobago and internationally. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.

Renaissance IPO ETF

NYSEARCA:IPO

The Renaissance IPO ETF (IPO) is an exchange-traded fund that is based on the FTSE Renaissance IPO index. The fund tracks a market cap-weighted index of recent US-listed IPOs. The fund acquires issues within 90 days or sooner after IPO and sells after 3 years. IPO was launched on Oct 14, 2013 and is managed by Renaissance.

Pharming Group

NASDAQ:PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial